Liminatus Pharma(NASDAQ) LIMNW

Market CapN/A

Since IPO (2025)-50%

5 YearN/A

1 Year-74%

1 Month+34%

$0.06

+26.90%

+0.01Today

Liminatus Pharma last closing stock price
Metric	Price	Date
Last close	USD 0.06	2026-08-31

Liminatus Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+22.39%	USD 0.05	2026-08-24
1 month	+34.31%	USD 0.04	2026-07-31
3 month	-38.67%	USD 0.09	2026-06-02
Year to date	+57.71%	USD 0.04	2025-12-31
1 year	-74.13%	USD 0.21	2025-08-29
Since inception	-49.86%	USD 0.11	2025-05-01

Liminatus Pharma Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.52M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$0.06

Volume

2,050

Open

$0.07

Price

$0.06

Volume

2,050

Open

$0.07

Previous Close

$0.06

Daily Range

$0.06 - $0.07

52-Week Range

$0.03 - $0.24

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$0.06

Volume

2,050

Open

$0.07

Previous Close

$0.06

Daily Range

$0.06 - $0.07

52-Week Range

$0.03 - $0.24

Estimated Earnings Date

N/A

LIMNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Liminatus Pharma

Liminatus Pharma, Inc. is an immuno-oncology firm based in La Palma, California, focused on developing innovative cancer treatments. The company is actively engaged in clinical trials to advance its therapeutic offerings in the biotechnology sector.

Products and Services

Immuno-oncology therapies targeting various cancer types
Clinical trial management and research services
Partnerships with research institutions for drug development

Growth Outlook

Significant investment in research and development, totaling $600,000 in Q2 2026
Increased cash reserves, reaching $3.02 million by Q2 2026
Strategic focus on expanding clinical trials to enhance product pipeline

Financial Highlights

Net income of -$1.41 million reported for Q2 2026
Operating expenses of $1.38 million in Q2 2026, reflecting ongoing investment in R&D
Cash flow from financing activities of $2.08 million in Q2 2026, indicating strong investor interest

Liminatus Pharma, Inc. operates in a competitive biotechnology landscape, with a clear focus on immuno-oncology. The company's commitment to research and development is evident in its substantial expenditures aimed at advancing its clinical trials. Despite reporting a net loss, the increase in cash reserves and financing activities suggests a robust interest from investors, which may support future growth initiatives. The strategic direction of Liminatus Pharma positions it well to capitalize on emerging opportunities in the oncology market, making it a noteworthy entity for potential investors to monitor.

AI Generated • Aug 18, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Cerritos, CA 90703, US

LIMNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

443.60%

Return on Capital

N/A

Return on Assets

-367.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

2.05K

Avg. Volume

3.17K

Financials (TTM)

Gross Profit

-$986.00

Operating Income

-$4.07M

EBITDA

-$12.44M

Operating Cash Flow

-$3.97M

Capital Expenditure

-$13.11K

Free Cash Flow

-$3.99M

Cash & ST Invst.

$3.02M

Total Debt

$1.44M

Liminatus Pharma Performance Analysis

Liminatus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Liminatus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-1477.6%
Q4	2025-12-31	-344.4%
Q1	2026-03-31	84.2%
Q2	2026-06-30	-25.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$468.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$1.41M

-1342.2%

EBITDA

-$1.38M

-882.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$3.02M

+125.5%

Total Debt

$1.44M

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.44M

+0.0%

Return on Assets

-3.68%

N/A

Return on Invested Capital

-11.19%

N/A

Free Cash Flow

-$970.00K

+89.2%

Operating Cash Flow

-$970.00K

+89.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

XRTXXORTX Therapeutics Inc.

XRTXXORTX Therapeutics Inc.$2.32-0.77%

GLMDGalmed Pharmaceuticals Ltd.

GLMDGalmed Pharmaceuticals Ltd.$4.12-1.20%

PTIXProtagenic Therapeutics, Inc.

PTIXProtagenic Therapeutics, Inc.$1.20+22.44%

CEROCERo Therapeutics Holdings, Inc.

CEROCERo Therapeutics Holdings, Inc.$0.01+22.99%

MLECMoolec Science S.A.

MLECMoolec Science S.A.$6.80+0.00%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$5.19-2.26%

BCTXZBriaCell Therapeutics Corp. Warrant

BCTXZBriaCell Therapeutics Corp. Warrant$0.15+11.11%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About LIMNW

What is the current price of Liminatus Pharma?

Liminatus Pharma is trading at $0.06 per share.

What is the 52-week range for Liminatus Pharma?

Over the past 52 weeks, Liminatus Pharma has traded between $0.03 and $0.24.

How much debt does Liminatus Pharma have?

Liminatus Pharma total debt is unavailable.

How much cash does Liminatus Pharma have on hand?

Liminatus Pharma does not have cash on hand data available.

What is Liminatus Pharma’s dividend yield?

Liminatus Pharma does not currently have a dividend yield.

Liminatus Pharma(NASDAQ) LIMNW

Liminatus Pharma Financials at a Glance

LIMNW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Liminatus Pharma

LIMNW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Liminatus Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LIMNW

What is the current price of Liminatus Pharma?

What is the 52-week range for Liminatus Pharma?

How much debt does Liminatus Pharma have?

How much cash does Liminatus Pharma have on hand?

What is Liminatus Pharma’s dividend yield?

Premium Investing Services